AnaptysBio, Inc.

Healthcare · Biotechnology · United States

Last price 48.28 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.44B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclus...